Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. American journal of kidney diseases : the official journal of the National Kidney Foundation Bomback, A. S., Appel, G. B., Gipson, D. S., Hladunewich, M. A., Lafayette, R., Nester, C. M., Parikh, S. V., Smith, R. J., Trachtman, H., Heeger, P. S., Ram, S., Rovin, B. H., Ali, S., Arceneaux, N., Ashoor, I., Bailey-Wickins, L., Barratt, J., Beck, L., Cattran, D. C., Cravedi, P., Erkan, E., Fervenza, F., Frazer-Abel, A. A., Fremeaux-Bacchi, V., Fuller, L., Gbadegesin, R., Hogan, J. J., Kiryluk, K., le Quintrec-Donnette, M., Licht, C., Mahan, J. D., Pickering, M. C., Quigg, R., Rheault, M., Ronco, P., Sarwal, M. M., Sethna, C., Spino, C., Stegall, M., Vivarelli, M., Feldman, D. L., Thurman, J. M. 2021

Abstract

Blocking the complement system as a therapeutic strategy has been proposed for numerous glomerular diseases but presents a myriad of questions and challenges, not the least of which is demonstrating efficacy and safety. In light of these potential issues and because there are an increasing number of anti-complement therapy trials either planned or underway, the National Kidney Foundation (NKF) facilitated an all-virtual format scientific workshop entitled, "Improving Clinical Trials for Anti-complement Therapies in Complement-mediated Glomerulopathies." Attended by patient representatives and experts in glomerular diseases, complement physiology, and clinical trial design, the aim of this workshop was to develop standards applicable for designing and conducting clinical trials for anti-complement therapies across a wide spectrum of complement-mediated glomerulopathies. Discussions focused on study design, subject risk assessment and mitigation, laboratory measurements and biomarkers to support these studies, and identification of optimal outcome measures to detect benefit, specifically for trials in complement-mediated diseases. This report summarizes the discussions from this workshop and outlines consensus recommendations.

View details for DOI 10.1053/j.ajkd.2021.07.025

View details for PubMedID 34571062